Sequential treatment strategy for malignant pleural effusion in non-small cell lung cancer with the activated epithelial grow factor receptor mutation.
With the advent of molecularly targeted therapy, it is necessary to reconsider the strategy for malignant pleural effusion in non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The aim of this study was to evaluate the efficacy of a two-line sequential treatment strategy in this patient subgroup. First-line treatment was gefitinib (250 mg/day) until disease progression. Second-line treatment was thoracoscopic talc pleurodesis followed by chemotherapy. Primary endpoints were the overall response and progression-free survival rates after first-line treatment, and the overall survival rate after first- and second-line treatment. Secondary endpoints were the success rate of thoracoscopic talc pleurodesis and gefitinib toxicity. Among the 76 patients enrolled, 61 (80%) were female and the median age was 62 years. The overall response rate after first-line treatment was 92.1% and median progression-free survival was 15 months. The success rate for thoracoscopic talc pleurodesis in 33 patients was 94%. Median follow-up was 35 months. Median overall survival was 39 months. The 1- and 3-year overall survival rates were 86.4% and 46.1%, respectively. The two-line sequential treatment strategy enhanced survival. These preliminary findings provide an insight into novel therapeutic models for malignant pleural effusion in NSCLC harbouring EGFR mutations.
a Department of Thoracic Surgery , First Affiliated Hospital, Fujian Medical University , Fuzhou City , People's Republic of China.
Jian-Bo
JB
Lin
a Department of Thoracic Surgery , First Affiliated Hospital, Fujian Medical University , Fuzhou City , People's Republic of China.
Fan-Cai
FC
Lai
a Department of Thoracic Surgery , First Affiliated Hospital, Fujian Medical University , Fuzhou City , People's Republic of China.
Xu
X
Li
b Lung Cancer Center, First Affiliated Hospital, Fujian Medical University , Fuzhou City , People's Republic of China.
Yuan-Rong
YR
Tu
b Lung Cancer Center, First Affiliated Hospital, Fujian Medical University , Fuzhou City , People's Republic of China.
Min
M
Lin
a Department of Thoracic Surgery , First Affiliated Hospital, Fujian Medical University , Fuzhou City , People's Republic of China.
Min-Lian
ML
Qiu
a Department of Thoracic Surgery , First Affiliated Hospital, Fujian Medical University , Fuzhou City , People's Republic of China.
Rong-Gang
RG
Luo
a Department of Thoracic Surgery , First Affiliated Hospital, Fujian Medical University , Fuzhou City , People's Republic of China.
Bo
B
Liu
b Lung Cancer Center, First Affiliated Hospital, Fujian Medical University , Fuzhou City , People's Republic of China.
Jing-Wei
JW
Lin
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications* / Q000628:therapy; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use; D016066:Pleural Effusion, Malignant / Q000188:drug therapy* / Q000209:etiology; D011799:Quinazolines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011799:Quinazolines; D016190:Carboplatin; D066246:ErbB Receptors; D017239:Paclitaxel; D000077156:Gefitinib
Epithelial growth factor receptor; malignant pleural effusion; non-small-cell lung cancer; pleurodesis; targeted therapy